Pharmicell Co.,Ltd.
Financials
Valuation Metrics
Pharmicell Co.,Ltd.'s Market Cap is ₩7831B. At end of 2025 it was ₩8719B. Ranked #359 of 2,419 in KR market (top 15%), #243 of 781 on KOSPI (top 31%), #40 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 17%) by Market Cap.
Investment Metrics(as of 2026-10-07)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 783.05B KRW | KR#359/2,419 Sec#40/231 |
| Revenue | 135.94B KRW | KR#1,239/2,419 Sec#76/231 |
| Net Income | 46.53B KRW | KR#441/2,419 Sec#26/231 |
| Total Assets | 184.15B KRW | KR#1,371/2,419 Sec#102/231 |
| Net Assets | 143.37B KRW | KR#1,170/2,419 Sec#85/231 |
| Employees | 146 | KR#1,348/2,419 Sec#109/231 |
| Value | ||
| P/E | 16.83x | KR#1,089/2,419 Sec#66/231 |
| P/B | 5.46x | KR#2,243/2,419 Sec#192/231 |
| PEG | 0.13x | KR#471/2,419 Sec#26/231 |
| P/S | 5.76x | KR#2,164/2,419 Sec#145/231 |
| EV/EBITDA | 18.00x | KR#948/2,419 Sec#56/231 |
| FCF Yield | 4.29% | KR#882/2,419 Sec#50/231 |
| Profitability | ||
| ROE | 32.46% | KR#47/2,419 Sec#5/231 |
| ROA | 25.27% | KR#27/2,419 Sec#5/231 |
| Op. Margin | 32.42% | KR#44/2,419 Sec#10/231 |
| Revenue Growth | 51.28% | KR#200/2,419 Sec#26/231 |
| Earnings Growth | 124.70% | KR#348/2,419 Sec#22/231 |
| Financial Health | ||
| Debt Ratio | 28.45% | KR#551/2,419 Sec#61/231 |
| Total Debt | 25.02B KRW | KR#1,305/2,419 Sec#103/231 |
| FCF | 33.60B KRW | KR#387/2,419 Sec#22/231 |
| Cash | 15.04B KRW | KR#1,424/2,419 Sec#111/231 |
| Current Ratio | 7.15x | KR#167/2,419 Sec#37/231 |
| Net Debt/EBITDA | 0.23x | KR#635/2,419 Sec#37/231 |
| Dividend | ||
| Div. Yield | 0.38% | KR#1,285/2,419 Sec#79/231 |
| Div. Growth | 150.00% | KR#65/2,419 Sec#2/231 |
| Performance | ||
| 1Y Return | 6.53% | KR#739/2,419 Sec#45/231 |
| 1M Return | 21.51% | KR#281/2,419 Sec#22/231 |
| From 52W High | -38.30% | KR#933/2,419 Sec#68/231 |
| 1Y MDD | -56.74% | KR#1,300/2,419 Sec#107/231 |
| Trading | ||
| Volume | 808,625 shares | KR#138/2,419 Sec#23/231 |
| Trading Value | 10.60B KRW | KR#256/2,419 Sec#30/231 |
| Foreign Own. | 8.54% | KR#531/2,419 Sec#45/231 |
| Per Share | ||
| EPS | 776 KRW | KR#821/2,419 Sec#60/231 |
| BPS | 2,389 KRW | KR#1,988/2,419 Sec#160/231 |
Company Info
Pharmicell, established in 1968 and renamed in 2011, is a specialized biotech company listed in 1988. It operates a biomedical division, manufacturing and selling the world's first stem cell therapy, and a biochemical division, producing pharmaceutical intermediates and eco-friendly phosphorus flame retardants, in addition to stem cell banking and cosmetics businesses. The company has developed and patented technologies for anticancer immunotherapy dendritic cells and neurological disorder treatments. Pharmicell is actively pursuing innovation through technology development in areas such as mRNA vaccine raw materials and artificial blood, and is headquartered in Gangnam-gu, Seoul.